Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer
March 15, 2021 06:15 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference
March 04, 2021 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Acquisition of Guide Therapeutics
February 23, 2021 08:34 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has...
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
January 19, 2021 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today...
Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors
January 11, 2021 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
December 05, 2020 07:00 ET
|
Beam Therapeutics
BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021 In Vivo Data from Makassar Base Editing Program...
The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
November 20, 2020 16:01 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...
Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD
November 13, 2020 08:00 ET
|
Beam Therapeutics
Novel Base Editors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation Correction than Required to Restore Glucose Homeostasis Previously Presented Data...
Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results
November 10, 2020 06:30 ET
|
Beam Therapeutics
BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99%...